Guided Therapeutics (GTHP) EBIT Growth (1y) (2011 - 2026)
Guided Therapeutics (GTHP) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -17.50% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 49.06% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 43.83% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 24.81% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 49.72% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 13.00% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 57.74% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 16.18% |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | 37.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.35% |
| Dec 31, 2025 | -32.96% |
| Sep 30, 2025 | 13.55% |
| Jun 30, 2025 | -16.49% |
| Mar 31, 2025 | -15.32% |
| Dec 31, 2024 | -10.10% |
| Sep 30, 2024 | 9.95% |
| Jun 30, 2024 | 56.48% |
| Mar 31, 2024 | 57.41% |
| Dec 31, 2023 | 48.84% |
| Sep 30, 2023 | 49.10% |
| Jun 30, 2023 | -109.90% |
| Mar 31, 2023 | -90.29% |
| Dec 31, 2022 | -117.93% |
| Sep 30, 2022 | -151.33% |
| Jun 30, 2022 | -27.81% |
| Mar 31, 2022 | 46.17% |
| Dec 31, 2021 | -51.04% |
| Sep 30, 2021 | -218.30% |
| Jun 30, 2021 | -52.03% |